Business Wire

Lexon’s Oblio Named as One of TIME’s 100 Best Inventions Of 2020

Share

20 years after making the cover of TIME with their flagship Tykho radio, French design brand Lexon is back on the prestigious publication to reiterate its mission to continuously create disruptive, useful and affordable design objects that improve our daily lives.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201125005899/en/

Oblio (Photo: Business Wire)

Oblio (Photo: Business Wire)

More than just highlighting the groundbreaking French invention, TIME award confirms Oblio’s position as a must-have innovation for today’s world, as it has been crafted in-house primarily as a sleek UV-C sanitizer to prevent the spread of harmful viruses and bacteria that are found on our smartphones, using its built-in UV-C LED technology located on its front interior. UV-C LEDs destroy and eradicate the DNA of microorganisms found in viruses, bacteria, mold, and germs.

Capable of fully sanitizing a single surface at a time, Oblio can deliver a 360° disinfection by simply flipping the phone to expose its second surface for a 20-minute cycle. In terms of effectiveness, Oblio has been proven through lab testing to kill 99.9% of viruses, including H1N1.

Since the beginning of the pandemic, we have seen a growing interest for this product category (UV sanitizer) and therefore, the market becoming rapidly populated with lots of unaesthetic neither truly legitimate solutions. In this context, we're extremely honored and proud to be recognized and awarded for our product's distinct design, its effectiveness and reliability to sanitize our daily essentials and the opportunity to become a must-have solution for today's home and offices.

With the help of media like TIME who are raising awareness around Oblio, with the support and trust of our retail partners who are listing it, we are together making UV-C technology becoming more popular and accessible to everyone, allowing us to collectively participate in a positive change, leveraging innovation to adapt to new behaviors and prevent the spread of virus, which is our common responsibility.” Says Boris Brault, Lexon CEO.

Also acting as a 10W wireless charger, Oblio can fully charge a smartphone in 3 hours and comes with an LED indicator that confirms the correct positioning and charging status of the mobile device.

Appropriately, 'Oblio' is rooted in the Italian meaning for “forgot” the native language of designers’ Manuela Simonelli & Andrea Quaglio. The name hints to the product’s vase shape, thoughtfully crafted to help people disconnect from their screens and enjoy the freedom to be more present for each other, while discreetly sanitizing any mobile phone and fast-charging all Qi-enabled smartphones such as the latest iPhone and Android.

“With such achievements, we’re also proving that France remains an indisputable territory where creativity, innovation and design are prerequisite to sustainable growth, and we hope we can inspire entrepreneurs to believe in their projects and bring them to life.” adds Brault.

Today, Oblio is already available at the most prominent retailers worldwide such as Best Buy, Nordstrom, MoMA Design Store in the US, Fnac Darty in Europe and many more, as well as the official online store: lexon-design.com.

About Lexon:
Since its creation in 1991, Lexon has relentlessly pushed the limits and created a difference in the world of design while remaining true to its commitment to make small objects useful, beautiful, innovative and affordable. Whether in electronics, audio, travel accessories, office or leisure, Lexon has established a special relationship with creativity and partnered with the best designers around the world to create timeless collections of lifestyle products. Following its recent acquisition by BOW Group, a global player in the lifestyle and wearable consumer markets, Lexon is writing a new chapter in its history, experiencing a staggering international growth and digital expansion. Today, with nearly 30 years of existence, more than 200 awards, collaboration with some of the most renowned designers, a retail presence in more than 90 countries across the Globe, Lexon has truly established itself as a worldly-known French design brand.

Contact information

International Media contact:
Annabel Corlay a.corlay@lexon-design.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF ® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy16.1.2021 22:15:00 CETPress release

Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine + bevacizumab (C-B) in a first-line setting for patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy.1 The data were announced today during an oral presentation at the 2021 ASCO Gastrointestinal Cancers Symposium (ASCO-GI). Patients with mCRC who are not eligible for chemotherapy face a large unmet need, with fewer treatment options available to them and lower survival rates. Colorectal cancer (CRC) makes up 9.7% of total global cancer cases, with almost 1.4 million new cases of CRC each year.2 In Europe, CRC is the second most common cause of death due to cancer, and those with a metastatic disease have a 5-year survival rate of just 11%.3 “For patients with metastatic colorectal cancer, those non-eligible for standard combination therapy have few options left and we are conti

H.I.G. Realty Invests in Production Studios & Content Hub in Madrid15.1.2021 09:00:00 CETPress release

H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with $43 billion of equity capital under management, announced today that one of its affiliates has invested in Madrid Content City, an approximately 140,000 square meter hub with state of the art audio-visual facilities, including production studios, production & post-production technical facilities, and a university focused on media studies. H.I.G. continues to add to its sizeable portfolio of real estate assets across Europe, consisting of both equity as well as debt investments, with a particular focus on its target market of value-added small and midcap opportunities. Riccardo Dallolio, Managing Director and Head of H.I.G. Europe Realty Partners, commented: “Madrid Content City will benefit from strong secular tailwinds underpinned by the boom in content production. The state-of-the-art studios and related facilities, the exceptional multinational tenant line-up with long term leases, and its critical mas

Eurofins, the global leader in analytical testing, expands worldwide face mask testing & certification capabilities15.1.2021 07:30:00 CETPress release

Since the start of the pandemic Eurofins (Paris:ERF) has tested thousands of models of surgical and hygienic masks and provided best-in-class speed and certification for PPEs globally, enabling these critical products to get market as fast as possible. Eurofins has developed global leading testing capabilities and certification services in the North America, Europe and Asia ensuring that PPE manufacturers are able to provide the indispensable support needed in the fight against the coronavirus. As of today, Eurofins is one of the few GLP certified and ISO/IEC 17025 accredited laboratory networks to fully cover all testing requirements for surgical/medical and hygienic masks by the FDA, EU regulations and many international and country-specific directives and guidelines such as CEN, CE Marking, ISO, ASTM or OECD. Our robust portfolio for masks includes globally accepted, safety and performance testing, virucidal, bacterial filtration, particle filtration, differential pressure, biocompa

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport ® (abobotulinumtoxinA) in five therapeutic indications15.1.2021 07:00:00 CETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced results from new analyses of pivotal Phase III clinical trial data to assess treatment intervals over repeat cycles of Dysport® (abobotulinumtoxinA [aboBoNT-A]) in five patient populations. AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations is being shared during the TOXINS 2021 conference, which is taking place virtually between 16-17 January 2020 and is organized by the International Neurotoxin Association.1-28 Ipsen is sharing 26 abstracts during the congress, with data including updates from the recently published surveys into the experience of patients and caregivers, data from the Phase IV ULIS-III trial, and ten abstracts focused on basic science research into neurotoxins.1-27 Spasticity is one of the most common and disabling conditions associated with many neurological conditions in adults and is characterized by velocity-dependent muscle hypertonia. Spasticity can lead to disabilit

Velodyne Lidar Commends NHTSA Plan to Update NCAP14.1.2021 21:58:00 CETPress release

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today commended the U.S. Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) plan to update to its New Car Assessment Program (NCAP). The NHTSA proposal would add four advanced driver assistance system (ADAS) capabilities to the NCAP, keeping pace with evolving safety technologies and providing much-needed information to consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005992/en/ Images show vehicle with lidar-based PAEB stopping before adult target @ 50% overlap (above) and vehicle with camera and radar-based PAEB crashing into adult target (below). (Photo: Velodyne Lidar, Inc.) NCAP is the U.S. Government’s premier consumer information program for evaluating vehicle safety performance. The NHTSA proposal to add ADAS technologies to the NCAP includes pedestrian automatic emergency braking, lane keeping support, blind spot warning and

Snow Software Recognized as a 2020 Gartner Peer Insights Customers’ Choice for Software Asset Management14.1.2021 20:39:00 CETPress release

Snow Software, the global leader in technology intelligence, today announced that the company was named a December 2020 Gartner Peer Insights Customers’ Choice for Software Asset Management (SAM) Tools. Gartner defines software asset management tools as technology that “automates many of the tasks required to maintain compliance with software licenses, thereby controlling software spending.” This is the fourth Gartner Peer Insights Customers’ Choice announcement for SAM, and Snow has earned the distinction all four times. Based solely on feedback from verified customers, Gartner Peer Insights Customers’ Choice reflects reviews and ratings published within the last 12 months. Snow received 100 reviews – the most of any vendor in the market – with an overall rating of 4.6 out of 5 as of January 12, 2021. Earlier this year, Snow was recognized as a Leader in Gartner’s 2020 Magic Quadrant for Software Asset Management Tools1 and received the highest scores in three out of four use cases in

Veristat Supported Marketing Applications for 10% of All FDA Novel Drug Approvals in 202014.1.2021 19:15:00 CETPress release

Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of the 2020 US Food and Drug Administration (FDA) novel drug approvals. The FDA approved 53 novel drugs, defined by the FDA as New Molecular Entities (NMEs)i, and Veristat regulatory, statistical, and medical writing experts were integral in preparing five of these NME New Drug Applications. Veristat also prepared NDA/BLAs for three non-NME FDA approvals and one Marketing Authorization Application (MAA) that received approval in Europe. "Despite the global challenges in 2020, Veristat continued to advance its mission of helping clients achieve regulatory approval of novel medical therapies," stated Patrick Flanagan, Chief Executive Officer at Veristat. "Now, more than ever, Veristat is focused on providing expert guidance to facilitate the rapid approval for therapies that improve the lives of patients and their families around the world." Ve

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom